Heart Diseases Clinical Trials in Durham, North Carolina
4 studies are recruiting for heart diseases in Durham, North Carolina right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.
Search these by distance from you
Studies now recruiting
-
Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure
The goal of this study is to evaluate the safety and efficacy of the BrioVAD System by demonstrating non-inferiority to the HeartMate 3 Left Ventricular Assist System when used for the treatment of advanced, refractory, left ventricular heart failure.
- Stage
- Not phased
- Ages
- 18 to 100
- Site
- Duke University, Durham, North Carolina
- Locations
- 47 in total
- Run by
- BrioHealth Solutions, Inc.
-
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Transthyretin amyloidosis (ATTR) is a disease where the normally occurring transthyretin (TTR) protein falls apart and forms amyloid, a sticky plaque-like substance that accumulates in different organs in the body and can cause damage to the organ. There are two ways that the TTR protein can fall a…
- Stage
- Phase 3
- Ages
- 18 to 75
- Site
- Duke University Medical Center, Durham, North Carolina
- Locations
- 104 in total
- Run by
- Eidos Therapeutics, a BridgeBio company
-
Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women
The central hypothesis of ROMA:Women is that the use of multiple arterial grafting (MAG) will improve clinical outcomes and quality of life (QOL) compared to single arterial grafting (SAG). The specific aims of ROMA:Women are: Aim 1: Determine the impact of MAG vs SAG on major adverse cardiac and c…
- Stage
- Not phased
- Ages
- 18 and older
- Site
- Duke University, Durham, North Carolina
- Locations
- 146 in total
- Run by
- Weill Medical College of Cornell University
-
PKP2-ACM Natural History Study
The goal of this study is to describe the natural history and clinical events for patients who have Arrhythmogenic Cardiomyopathy with Pathogenic Plakophilin-2 Variants (PKP2-ACM) managed with standard of care.
- Stage
- Not phased
- Ages
- 12 and older
- Site
- Duke University, Durham, North Carolina
- Locations
- 3 in total
- Run by
- Rocket Pharmaceuticals Inc.
How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.
What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.
Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.